Quarterly report [Sections 13 or 15(d)]

Schedule of Accounts Payable to Related Party (Details)

v3.25.2
Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2025
Jun. 30, 2025
Jun. 30, 2024
Defined Benefit Plan Disclosure [Line Items]      
Beginning balance $ 1,183,000 [1] $ 1,183,000 [1] $ 3,515,000
Invoices, net   626,000 778,000
Payments in cash   (364,000) (2,641,000)
Payments in common stock, at fair value   (810,000)
Payments in pre-funded warrants, at fair value $ (847,000) (847,000)
Ending balance   $ 598,000 [1] $ 842,000
[1] Accounts Payable to Cytovance, a related party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock. See Note 7 – Commitments and Contingencies, Significant Agreements.